DDL-218

• Description:

  DDL-218 is an orally active and potent SirT1 inhibitor. DDL-218 enhances SirT1 in ApoE4-expressing neurons and a murine AD model. DDL-218 can be used in the study of Alzheimer's disease[1].

• UNSPSC:

  12352005

• Target:

  Sirtuin

• Related Pathways:

  Cell Cycle/DNA Damage; Epigenetics

• Field of Research:

  Neurological Disease

• Purity:

  99.49

• Smiles:

  N[C@@H](C)C(OC(C)(C)CC1=CC=NC=C1)=O

• Molecular Formula:

  C12H18N2O2

• Molecular Weight:

  222.28

• References & Citations:

  [1]Campagna J, et al. Discovery of an ApoE4-targeted small-molecule SirT1 enhancer for the treatment of Alzheimer's disease. Sci Rep. 2025 Apr 23;15 (1) :14028.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  4°C (Powder, protect from light)

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• CAS Number:

  [2767324-34-3]